Evaluate usability of self injection with mepolizumab autoinjector or prefilled syringe

Trial description: Mepolizumab has been associated with significant reductions in exacerbation rates of asthma and use of oral corticosteroids (OCS), especially in participants with elevated blood eosinophil counts. Mepolizumab was first approved in 2015 under the trade name NUCALA®, which was available as vial with lyophile and injected personally by a healthcare provider. In 2019, two new application forms – autoinjector (AI) and prefilled syringe (PFS) – received European market authorization. They can be administered directly by the participants themselves or by a caregiver, after the participant/caregiver have received training by a healthcare provider and the specific participant caregiver was considered adequate for self-application. This offers a paradigm shift from an office or hospital-based treatment approach to at home care and treatment. The NUCALA AI is a pen and injects the full dose of mepolizumab solved in liquid automatically after having been positioned on the skin and being activated by downwards pressure. The NUCALA PFS is a classical syringe with a fixed needle. The aims of this non-interventional study are to qualify as well as quantify (a) physicians and participants attitudes towards this novel approach in respiratory medicine, (b) to analyze outcomes in participants having been switched successfully or non-successfully to at home therapy with the NUCALA AI or PFS, and (c) to correlate attitudes and outcomes. Approximately 400 participants will be enrolled in this study and the study duration will be around 3 years. NUCALA is a registered trademark of GlaxoSmithKline (GSK) group of companies.